Slow Jogging for Breast Cancer Survivors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This investigator-initiated, single-center trial compares a structured slow jogging program plus usual care versus usual care alone in hormone receptor-positive breast cancer survivors who finished primary treatment within the past year. Participants are randomized in blocks of six to ensure balanced groups. The primary outcome is sleep quality measured by the CPSQI, with secondary outcomes including cancer-related fatigue and health-related quality of life. The study is conducted at Mackay Memorial Hospital in Taipei, Taiwan, and uses a smartphone-enabled platform to support the intervention and education components.

Why it matters

Who can join: the full rules

Inclusion Criteria

1. Female breast cancer survivors aged 20 years or older.
2. Histologically confirmed hormone receptor-positive breast cancer (Stage I-IV) and considered suitable for exercise intervention by the treating physician.
3. Completed primary cancer treatment (surgery, chemotherapy, or radiotherapy) within the previous 12 months; participants receiving ongoing anti-HER2 targeted therapy and/or endocrine therapy are eligible.
4. Able to independently operate a smartphone and willing to install and use the study application.
5. Self-reported sleep disturbance within the previous two weeks, defined as a Single-item Sleep Quality Scale (SQS) score ≥ 6.
6. Willing to participate and provide written informed consent.

Exclusion Criteria

1. History of cancer treatment-related cardiovascular complications or judged by the treating physician to be unsuitable for exercise.
2. Musculoskeletal disorders affecting lower-extremity function (e.g., plantar fasciitis, knee osteoarthritis, ankle degenerative disease) that limit exercise participation.
3. Currently participating in another structured moderate- or vigorous-intensity aerobic exercise program (≥3 sessions/week, ≥30 minutes/session for ≥3 consecutive weeks).
4. Any other medical or psychological condition judged by the investigator to interfere with safe participation or completion of the study.

Where it's running

• Taipei Mackay Memorial Hospital
  Taipei, Taipei City, Taiwan Recruiting

Study contacts

• Study coordinator: Hsin-Yi Ku, RN, MSN
• Email: shinyi.6178@mmh.org.tw
• Phone: +886-2-2543-3535

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Improved Facial Skin Quality After VYC-12L for Breast Cancer Survivors

  This study tests whether intradermal injections of VYC-12L can improve facial skin quality and quality of life in adults who have completed breast cancer treatment.

  Recruiting Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia · Murcia, Murcia · NCT07917117

• Breast cancer subtypes and outcomes in Colombian women

  This study looks back at medical records of women with breast cancer to see how different molecular subtypes relate to survival and recurrence in a single Colombian hospital.

  Recruiting Fundación Santa Fe de Bogota · Bogotá, Bogota D.C. · NCT07856225

• Multimodal psychosomatic symptom care for breast cancer: personalized acupuncture care guided by shared decision-making

  This study tests whether personalized acupuncture options (manual acupuncture, ear acupuncture, or both) can help women with breast cancer who have anxiety, sleep problems, or fatigue, compared to routine nursing care.

  Recruiting at 3 sites First Teaching Hospital of Tianjin University of Traditional Chinese Medicine · Tianjin and 2 other locations · NCT07763587

• Methylscape test in body fluids for multi-cancer detection in Colombia

  A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07741435

• Benchmarking AI language models against tumor boards for oncology treatment decisions

  This project tests whether frontier AI language models can match the treatment recommendations of multidisciplinary tumor boards for common cancers using standardized synthetic cases.

  Recruiting Assistance Publique - Hôpitaux de Paris · Boulogne-Billancourt and 4 other locations · NCT07739121

• AI-powered pre-treatment MRI to predict chemotherapy response in HR+/HER2- breast cancer

  This study tests whether AI analysis of baseline DCE-MRI can forecast which HR+/HER2- breast cancer patients will benefit most from neoadjuvant chemotherapy.

  Recruiting at 5 sites Fujian Cancer Hospital · Fuzhou, Fujian and 4 other locations · NCT07702708

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.